Comprehensive league table of cost-utility ratios: A systematic review of cost-effectiveness evidence for health policy decisions in India

被引:2
|
作者
Shah, Komal [1 ]
Singh, Malkeet [2 ]
Kotwani, Priya [3 ]
Tyagi, Kirti [2 ]
Pandya, Apurvakumar [4 ]
Saha, Somen [1 ]
Saxena, Deepak [1 ]
Rajshekar, Kavitha [2 ]
机构
[1] Indian Inst Publ Hlth Gandhinagar IIPHG, Gandhinagar, India
[2] HTAIn Secretariat, Dept Hlth Res, New Delhi, India
[3] Jhpiego, New Delhi, India
[4] Parul Univ, Parul Inst Publ Hlth, Fac Med, Vadodara, India
关键词
country-specific "league table; Health Technology Assessment; India; cost-effectiveness; policy decision-making process; MIDDLE-INCOME COUNTRIES; ECONOMIC-EVALUATION; ROTAVIRUS VACCINATION; TUBERCULOSIS-CONTROL; TREATMENT COVERAGE; HIV PREVENTION; IMMUNIZATION; IMPACT; INTERVENTIONS; PROGRAM;
D O I
10.3389/fpubh.2022.831254
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and objectives: Although a relatively recent concept for developing countries, the developed world has been using League Tables as a policy guiding tool for a comprehensive assessment of health expenditures; country-specific "League tables " can be a very useful tool for national healthcare planning and budgeting. Presented herewith is a comprehensive league table of cost per Quality Adjusted Life Years (QALY) or Disability Adjusted Life Years (DALY) ratios derived from Health Technology Assessment (HTA) or economic evaluation studies reported from India through a systematic review. Methods: Economic evaluations and HTAs published from January 2003 to October 2019 were searched from various databases. We only included the studies reporting common outcomes (QALY/DALY) and methodology to increase the generalizability of league table findings. To opt for a uniform criterion, a reference case approach developed by Health Technology Assessment in India (HTAIn) was used for the reporting of the incremental cost-effectiveness ratio. However, as, most of the articles expressed the outcome as DALY, both (QALY and DALY) were used as outcome indicators for this review. Results: After the initial screening of 9,823 articles, 79 articles meeting the inclusion criteria were selected for the League table preparation. The spectrum of intervention was dominated by innovations for infectious diseases (33%), closely followed by maternal and child health (29%), and non-communicable diseases (20%). The remaining 18% of the interventions were on other groups of health issues, such as injuries, snake bites, and epilepsy. Most of the interventions (70%) reported DALY as an outcome indicator, and the rest (30%) reported QALY. Outcome and cost were discounted at the rate of 3 by 73% of the studies, at 5 by 4% of the studies, whereas 23% of the studies did not discount it. Budget impact and sensitivity analysis were reported by 18 and 73% of the studies, respectively. Interpretation and conclusions: The present review offers a reasonably coherent league table that reflects ICER values of a range of health conditions in India. It presents an update for decision-makers for making decisions about resource allocation.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Cost-Effectiveness and Cost-Utility of Internet-Based Computer Tailoring for Smoking Cessation
    Smit, Eline Suzanne
    Evers, Silvia M. A. A.
    de Vries, Hein
    Hoving, Ciska
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2013, 15 (03) : 55 - 70
  • [22] Systematic methodological review of health state values in glaucoma cost-utility analyses
    Kennedy, Kevin
    Sarohia, Gurkaran
    Podbielski, Dominik
    Pickard, Simon
    Tarride, Jean-Eric
    Xie, Feng
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (08) : 1417 - 1435
  • [23] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Gallehzan, Nasrin Abulhasanbeigi
    Khosravi, Majid
    Jamebozorgi, Khosro
    Mir, Nazanin
    Jalilian, Habib
    Soleimanpour, Samira
    Hoseini, Saeed
    Rezapour, Aziz
    Eshraghi, Abbas
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [24] Cost-effectiveness and cost-utility analysis of a work-place smoking cessation intervention with and without financial incentives
    van denBrand, Floor A.
    Nagelhout, Gera E.
    Winkens, Bjorn
    Chavannes, Niels H.
    vanSchayck, Onno C. P.
    Evers, Silvia M. A. A.
    ADDICTION, 2020, 115 (03) : 534 - 545
  • [25] Cost and Cost-Effectiveness of the Mediterranean Diet: An Update of a Systematic Review
    Colaprico, Corrado
    Crispini, Davide
    Rocchi, Ilaria
    Kibi, Shizuka
    De Giusti, Maria
    La Torre, Giuseppe
    NUTRIENTS, 2024, 16 (12)
  • [26] Cost-effectiveness and cost-utility of long-term management strategies for heartburn
    Goeree, R
    O'Brien, BJ
    Blackhouse, G
    Marshall, J
    Briggs, A
    Lad, R
    VALUE IN HEALTH, 2002, 5 (04) : 312 - 328
  • [27] A cceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
    Griffiths, Elizabeth A.
    Hendrich, Janek K.
    Stoddart, Samuel D. R.
    Walsh, Sean C. M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 463 - 476
  • [28] Evidence on the cost and cost-effectiveness of palliative care: A literature review
    Smith, Samantha
    Brick, Aoife
    O'Hara, Sinead
    Normand, Charles
    PALLIATIVE MEDICINE, 2014, 28 (02) : 130 - 150
  • [29] Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review
    Getchell, Marya
    Mantaring, Ericka Joinelle
    Yee, Kaisin
    Pronyk, Paul
    VACCINE, 2023, 41 (14) : 2320 - 2328
  • [30] Enhanced recovery following hip and knee arthroplasty: a systematic review of cost-effectiveness evidence
    Pritchard, Mark G.
    Murphy, Jacqueline
    Cheng, Lok
    Janarthanan, Roshni
    Judge, Andrew
    Leal, Jose
    BMJ OPEN, 2020, 10 (01):